Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.48 |
| ▸ | ABL1 | P00519 | 7/20 | 0.46 |
| ▸ | BCR | P11274 | 5/20 | 0.46 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.43 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.43 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | HCK | P08631 | 1/20 | 0.42 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13436557 | 0.88 | ABL1 (0.51) | BRAFABL1BCR | |
| SCHEMBL13436167 | 0.84 | BRAF (0.55) | BRAFABL1BCRDDR1DDR2 | |
| SCHEMBL13436601 | 0.83 | ABL1 (0.49) | BRAFABL1BCRGPR142MAP4K2 | |
| SCHEMBL15869647 | 0.83 | BRAF (0.47) | BRAFABL1BCRMAP3K7MAP4K2 | |
| SCHEMBL12398369 | 0.82 | BRAF (0.62) | BRAFABL1BCRGPR142DDR1 | |
| SCHEMBL12398367 | 0.81 | ABL1 (0.70) | BRAFABL1BCRGPR142MAP3K7 | |
| SCHEMBL15869559 | 0.81 | BRAF (0.54) | BRAF | |
| SCHEMBL15869561 | 0.81 | BRAF (0.55) | BRAFABL1BCRHCKNR2C2 | |
| SCHEMBL13436165 | 0.81 | BRAF (0.45) | BRAFABL1BCRMAP3K7MAP4K2 | |
| SCHEMBL15869557 | 0.77 | ABL1 (0.48) | BRAFABL1BCRGPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350052-B1 | ANTIPROLIFERATIVE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-13 | — | — | EP | claimed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | claimed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| CN-102227421-A | Anti-proliferation compounds | BOEHRINGER INGELHEIM INT | 2011-10-26 | — | — | CN | claimed |
| EP-2350052-B1 | ANTIPROLIFERATIVE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010034838-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | BRAF 433/4885ABL1 234/4885BCR 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.